This legislative text aims to amend the Federal Trade Commission Act to prohibit the practice of "product hopping" in the pharmaceutical industry. Product hopping occurs when drug manufacturers make minor changes to existing medications to prevent patients from switching to more affordable generic alternatives. The goal of this legislation is to enhance competition in the drug market, ultimately making medications more affordable and accessible for consumers.